In patients with stage II-III HER2+ breast cancer who were not treated with neoadjuvant therapy, without having knowledge of response to neoadjuvant therapy (i.e. pCR or not) after chemotherapy, what is your preferred adjuvant HER2 directed therapy?  

I largely agree with @Charles L. Shapiro. I am also underwhelmed by the APHINITY data and limit TDM-1 to patients with residual disease after neoadjuvant therapy that includes trastuzumab +/- pertuzumab. And, while I am sure that they exist, I have yet to see the patient to whom I would recommend ne...

At my institution, any woman who presents with HER2 over-expressing breast cancer about 2 cm or larger will receive neoadjuvant HER2-targeted chemotherapy. This case describes a women who went surgery first. For < 3 cm and node-negative, the 3-year invasive disease survival rate was 98.7% with 12...